LuminaScanX South Africa Diagnostic Centres Business Plan — Appendix A: Detailed Financial Statements

Jump to sectionAll 19 pages
Appendix A · 17 of 19

Detailed Financial Statements

This appendix consolidates the integrated three-statement projection and the principal supporting exhibits. All figures are in South African Rand millions unless stated; the balance sheet ties to zero in every year.

Integrated five-year summary

R millions

Y1

Y2

Y3

Y4

Y5

Revenue

95

185

320

480

710

EBITDA

18

46

92

145

228

EBIT

(17.8)

(0.1)

32.1

74.1

149.1

Net interest

19.5

23.6

28.4

31.2

30.0

Profit before tax

(37.3)

(23.7)

3.7

42.9

119.1

Net profit after tax

(37.3)

(23.7)

3.5

40.6

93.3

Operating cash flow

(13.8)

10.8

45.9

90.7

142.3

Capital expenditure

(295.0)

(90.0)

(120.0)

(95.0)

(70.0)

Closing cash

11.2

21.9

27.8

28.4

50.7

Net PP&E

243.2

291.1

355.2

383.3

378.4

Total assets

290.3

363.9

458.2

516.5

578.3

Total debt

150.0

185.0

220.0

225.0

175.0

Total equity

132.7

164.1

212.6

253.1

346.5

Net working capital

12.3

24.1

41.6

62.4

92.3

Figure 32. Five-year KPI dashboard.

Year-1 quarterly cash phasing (illustrative)

Year 1 cash is phased to reflect the platform build: the R320 million raise is received at close, capital is deployed through the year as centres are fitted out and equipped, and operating cash builds as the flagships open and volumes ramp.

R millions

Q1

Q2

Q3

Q4

FY1

Revenue

11

19

28

37

95

EBITDA

1

3

6

8

18

Capex deployed

(120)

(85)

(45)

(25)

(275)

Closing cash

190

118

72

11

11

Supporting exhibits

Figure 33. Revenue and EBITDA trajectory (R million).
Figure 34. EBITDA and EBITDA margin, Years 1–5.
Figure 35. Revenue versus EBIT breakeven threshold (R million).
Figure 36. Operating cost structure at scale.
Figure 37. Illustrative price positioning by modality (R per study).
Figure 38. Market opportunity: TAM / SAM / SOM.